H.C. Wainwright Reiterates Buy Rating on UroGen Pharma (URGN)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
| (NASDAQ: URGN) | Delayed: 34.04 -0.45 (1.3%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $34.49 | 52 Week High | $ | |||
| Open | $34.64 | 52 Week Low | $ | |||
| Day High | $35.00 | P/E | N/A | |||
| Day Low | $33.87 | EPS | $ | |||
| Volume | 670,047 | |||||
